Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
+9.61%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$3.86B
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,919
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| 1 |
Kenvue
KVUE
|
$439M |
| 2 |
AT&T
T
|
$437M |
| 3 |
Cummins
CMI
|
$427M |
| 4 |
Bunge Global
BG
|
$340M |
| 5 |
DaVita
DVA
|
$232M |
Top Sells
| 1 |
Qualcomm
QCOM
|
$453M |
| 2 |
AbbVie
ABBV
|
$447M |
| 3 |
Phillips 66
PSX
|
$441M |
| 4 |
D.R. Horton
DHI
|
$440M |
| 5 |
Booking.com
BKNG
|
$405M |
Sector Composition
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 11.92% |
| 4 | Technology | 11.17% |
| 5 | Healthcare | 10.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1351
89bio
ETNB
$1.27B
| $25K | ﹤0.01% |
+2,146
| New | +$25K |
|
1352
Fate Therapeutics
FATE
$111M
| $24.9K | ﹤0.01% |
+3,394
| New | +$24.9K |
|
1353
NETSCOUT
NTCT
$1.78B
| $24.9K | ﹤0.01% |
1,138
+261
| +30% | +$5.7K |
|
1354
Myriad Genetics
MYGN
$643M
| $24.7K | ﹤0.01% |
+1,160
| New | +$24.7K |
|
1355
Arcturus Therapeutics
ARCT
$484M
| $24.7K | ﹤0.01% |
+731
| New | +$24.7K |
|
1356
MaxLinear
MXL
$1.38B
| $24.4K | ﹤0.01% |
1,307
+964
| +281% | +$18K |
|
1357
Replimune Group
REPL
$471M
| $24.4K | ﹤0.01% |
+2,984
| New | +$24.4K |
|
1358
MacroGenics
MGNX
$111M
| $24.1K | ﹤0.01% |
+1,639
| New | +$24.1K |
|
|
FARO
1359
DELISTED
Faro Technologies
FARO
| $23.9K | ﹤0.01% |
1,109
| – | – |
|
1360
Avidity Biosciences
RNA
$6.18B
| $23.8K | ﹤0.01% |
+931
| New | +$23.8K |
|
1361
Xencor
XNCR
$600M
| $23.5K | ﹤0.01% |
+1,064
| New | +$23.5K |
|
1362
Axcelis
ACLS
$2.57B
| $23.3K | ﹤0.01% |
209
+65
| +45% | +$7.25K |
|
1363
Booz Allen Hamilton
BAH
$12.5B
| $23.3K | ﹤0.01% |
157
| – | – |
|
1364
4D Molecular Therapeutics
FDMT
$326M
| $23.2K | ﹤0.01% |
+729
| New | +$23.2K |
|
1365
Sana Biotechnology
SANA
$762M
| $23.1K | ﹤0.01% |
+2,309
| New | +$23.1K |
|
1366
Vir Biotechnology
VIR
$721M
| $22.3K | ﹤0.01% |
2,203
+2,044
| +1,286% | +$20.7K |
|
1367
CommScope
COMM
$3.59B
| $22.1K | ﹤0.01% |
16,842
+5,856
| +53% | +$7.67K |
|
1368
Cogent Biosciences
COGT
$1.77B
| $22K | ﹤0.01% |
+3,279
| New | +$22K |
|
|
INFN
1369
DELISTED
Infinera Corporation Common Stock
INFN
| $22K | ﹤0.01% |
3,641
+2,762
| +314% | +$16.7K |
|
1370
Zentalis Pharmaceuticals
ZNTL
$118M
| $21.8K | ﹤0.01% |
+1,386
| New | +$21.8K |
|
1371
Travere Therapeutics
TVTX
$1.89B
| $21.4K | ﹤0.01% |
+2,771
| New | +$21.4K |
|
1372
Soleno Therapeutics
SLNO
$3.84B
| $21K | ﹤0.01% |
+491
| New | +$21K |
|
1373
ADMA Biologics
ADMA
$3.92B
| $20.9K | ﹤0.01% |
+3,174
| New | +$20.9K |
|
1374
Apogee Therapeutics
APGE
$2.29B
| $20.6K | ﹤0.01% |
+310
| New | +$20.6K |
|
|
ECC
1375
Eagle Point Credit Co
ECC
$951M
| – | – |
0
| – | -$18.1K |
|